I think by the looks of things Sarepta is really just pivoted and building itself into a Gene Therapy power house …. they are certainly the drugs they are leading with in clinic now & over the past 2 years Sarepta has signed 6 ? 7 ? deals all of which have been on building their gene therapy position - no deals outside of that.
Did they take anything at the end of the 4 year collaboration with MU, Fletcher / Wilton and establishing STL ? By the looks of it no, unless all parties are keeping it quiet ? Would be interesting to know if STL stayed active ? Although I would assume any extension would have been released ?
PYC Price at posting:
5.8¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)